Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 175.00 | |
5 mg | In stock | $ 372.00 | |
10 mg | In stock | $ 556.00 | |
25 mg | In stock | $ 896.00 | |
50 mg | In stock | $ 1,220.00 | |
100 mg | In stock | $ 1,650.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 492.00 |
Description | Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease. |
Targets&IC50 | BACE1 (human):11 nM , BACE1 (mouse):10 nM |
In vitro | Umibecestat is a potent inhibitor of BACE-1 that is selective for BACE-1 over other human pepsin-like aspartic proteases, including BACE-2 and cathepsin D[1]. |
In vivo | In both rat brain and CSF, Umibecestat (CNP520) (1.5-51.3 mg/kg; given by oral gavage; 72 hours) shows dose-dependent effects on Aβ40 and a long duration of action. Umibecestat (3.1 mg/kg; p.o.; 7 days) shows a > 75% reduction on Aβ40 and Aβ42 in CSF after dosing and returns slowly to baseline over the next 7 days[1]. |
Synonyms | CNP520 |
Molecular Weight | 513.8 |
Formula | C19H15ClF7N5O2 |
CAS No. | 1387560-01-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (184.90 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Umibecestat 1387560-01-1 Neuroscience BACE Beta-secretase inhibit CNP520 β-Secretase CNP 520 Inhibitor CNP-520 inhibitor